Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist

January 17, 2018

Responsive image

NEW HAVEN, Conn., Jan. 18, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (Biohaven or the “Company”) and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may pr…

Category: Precious Metals